Artiva Biotherapeutics (NASDAQ:ARTV) Director Ra Capital Management, L.P. Acquires 124,893 Shares of Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. bought 124,893 shares of Artiva Biotherapeutics stock in a transaction that occurred on Tuesday, June 16th. The shares were acquired at an average price of $8.89 per share, for a total transaction of $1,110,298.77. Following the acquisition, the director directly owned 16,763,043 shares in the company, valued at approximately $149,023,452.27. This represents a 0.75% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, June 15th, Ra Capital Management, L.P. acquired 15,414 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $8.99 per share, for a total transaction of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. acquired 391,019 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $8.57 per share, for a total transaction of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. acquired 548,580 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $7.91 per share, for a total transaction of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. bought 103 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $7.00 per share, for a total transaction of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. bought 479,039 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $6.91 per share, for a total transaction of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. bought 6,510,416 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $11.52 per share, for a total transaction of $74,999,992.32.

Artiva Biotherapeutics Stock Performance

Shares of Artiva Biotherapeutics stock opened at $8.91 on Wednesday. The firm has a market cap of $220.26 million, a PE ratio of -2.52 and a beta of 2.38. The firm’s 50-day simple moving average is $9.02 and its 200-day simple moving average is $6.23. Artiva Biotherapeutics, Inc. has a 1 year low of $1.47 and a 1 year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). On average, equities analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP bought a new stake in shares of Artiva Biotherapeutics during the 1st quarter valued at about $131,000. Sanctuary Advisors LLC bought a new stake in shares of Artiva Biotherapeutics during the 1st quarter valued at about $139,000. Simplify Asset Management Inc. bought a new stake in shares of Artiva Biotherapeutics during the 1st quarter valued at about $150,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Artiva Biotherapeutics during the 4th quarter valued at about $91,000. Finally, Marshall Wace LLP bought a new stake in shares of Artiva Biotherapeutics during the 4th quarter valued at about $341,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Needham & Company LLC restated a “buy” rating and issued a $41.00 target price on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. HC Wainwright upped their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Finally, Wedbush upped their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.